Thryv Therapeutics Inc.
@thryvtrx.bsky.social
We will relentlessly pursue a precision medicine approach targeting SGK1 to enable people to live their best lives. Without limits.
Visit our website: https://thryvtrx.com/
Visit our website: https://thryvtrx.com/
Nobody should miss a chance to live fully.
Through myQTwave, lived experiences help guide patient-centered care—so future generations of people with LQTS can thrive without limits.
It starts with you.
Together, we move forward. 💚
🌊 Learn more at www.myQTwave.com
Through myQTwave, lived experiences help guide patient-centered care—so future generations of people with LQTS can thrive without limits.
It starts with you.
Together, we move forward. 💚
🌊 Learn more at www.myQTwave.com
December 17, 2025 at 9:14 PM
Nobody should miss a chance to live fully.
Through myQTwave, lived experiences help guide patient-centered care—so future generations of people with LQTS can thrive without limits.
It starts with you.
Together, we move forward. 💚
🌊 Learn more at www.myQTwave.com
Through myQTwave, lived experiences help guide patient-centered care—so future generations of people with LQTS can thrive without limits.
It starts with you.
Together, we move forward. 💚
🌊 Learn more at www.myQTwave.com
We’re pleased to share positive Phase 1 results for THRV-1268, showing clear target engagement and QTcF shortening in obese participants. These data support SGK1 inhibition in cardiometabolic disease & HF. Phase 2a Aspire-HF planned for 2026.
🔗 www.newswire.ca/news-release...
🔗 www.newswire.ca/news-release...
December 17, 2025 at 2:28 PM
We’re pleased to share positive Phase 1 results for THRV-1268, showing clear target engagement and QTcF shortening in obese participants. These data support SGK1 inhibition in cardiometabolic disease & HF. Phase 2a Aspire-HF planned for 2026.
🔗 www.newswire.ca/news-release...
🔗 www.newswire.ca/news-release...
Thryv Therapeutics is heading to SF for the 44th JPM Conference! We’ll be sharing updates on our SGK1 inhibitor programs and upcoming milestones.
Schedule a meeting: [email protected]
#JPM2026 #BiotechNews #LifeSciences #CardiacHealth #SGK1
Schedule a meeting: [email protected]
#JPM2026 #BiotechNews #LifeSciences #CardiacHealth #SGK1
December 11, 2025 at 5:12 PM
Thryv Therapeutics is heading to SF for the 44th JPM Conference! We’ll be sharing updates on our SGK1 inhibitor programs and upcoming milestones.
Schedule a meeting: [email protected]
#JPM2026 #BiotechNews #LifeSciences #CardiacHealth #SGK1
Schedule a meeting: [email protected]
#JPM2026 #BiotechNews #LifeSciences #CardiacHealth #SGK1
We’re thrilled to welcome Matt Killeen, PhD, as CBO at Thryv!
With deep expertise in cardiovascular & genetic diseases, Matt will help drive our BD strategy and advance THRV-1268 toward Phase 2/3.
Link: loom.ly/4kCC3Oo
#SGK1 #Cardiology #Biotech #LQTS #HeartFailure #AFib
With deep expertise in cardiovascular & genetic diseases, Matt will help drive our BD strategy and advance THRV-1268 toward Phase 2/3.
Link: loom.ly/4kCC3Oo
#SGK1 #Cardiology #Biotech #LQTS #HeartFailure #AFib
December 2, 2025 at 2:23 PM
We’re thrilled to welcome Matt Killeen, PhD, as CBO at Thryv!
With deep expertise in cardiovascular & genetic diseases, Matt will help drive our BD strategy and advance THRV-1268 toward Phase 2/3.
Link: loom.ly/4kCC3Oo
#SGK1 #Cardiology #Biotech #LQTS #HeartFailure #AFib
With deep expertise in cardiovascular & genetic diseases, Matt will help drive our BD strategy and advance THRV-1268 toward Phase 2/3.
Link: loom.ly/4kCC3Oo
#SGK1 #Cardiology #Biotech #LQTS #HeartFailure #AFib
We’re highlighting new updates on myQTwave, our remote study for people with LQT2/LQT3. Thank you to advocate Tiffany Stayer for her perspective.
Full announcement: loom.ly/9yELMXU
#LQTS #myQTwave #DigitalHealth
Full announcement: loom.ly/9yELMXU
#LQTS #myQTwave #DigitalHealth
December 1, 2025 at 7:25 PM
We’re highlighting new updates on myQTwave, our remote study for people with LQT2/LQT3. Thank you to advocate Tiffany Stayer for her perspective.
Full announcement: loom.ly/9yELMXU
#LQTS #myQTwave #DigitalHealth
Full announcement: loom.ly/9yELMXU
#LQTS #myQTwave #DigitalHealth
We’re excited to welcome Amy Rudolph, PhD, to Thryv Therapeutics’ Board! Her medical affairs and cardiovascular drug development expertise will help advance THRV-1268 and our SGK1 platform.
Read more: www.newswire.ca/news-release...
#SGK1 #Cardiology #Biotech #LQTS #HeartFailure #AFib
Read more: www.newswire.ca/news-release...
#SGK1 #Cardiology #Biotech #LQTS #HeartFailure #AFib
November 19, 2025 at 3:48 PM
We’re excited to welcome Amy Rudolph, PhD, to Thryv Therapeutics’ Board! Her medical affairs and cardiovascular drug development expertise will help advance THRV-1268 and our SGK1 platform.
Read more: www.newswire.ca/news-release...
#SGK1 #Cardiology #Biotech #LQTS #HeartFailure #AFib
Read more: www.newswire.ca/news-release...
#SGK1 #Cardiology #Biotech #LQTS #HeartFailure #AFib
Exciting updates from #AHA25! 🎉
Our CMO, Dr. Amy Sehnert, and co-founder, Dr. Saumya Das, presented 3 posters on SGK1 inhibition in heart failure.
Our new preprint, “A novel SGK1 inhibitor improves cardiac structure & function”, is now live: researchsquare.com/article/rs-7...
#HeartFailure #SGK1
Our CMO, Dr. Amy Sehnert, and co-founder, Dr. Saumya Das, presented 3 posters on SGK1 inhibition in heart failure.
Our new preprint, “A novel SGK1 inhibitor improves cardiac structure & function”, is now live: researchsquare.com/article/rs-7...
#HeartFailure #SGK1
November 11, 2025 at 7:15 PM
Exciting updates from #AHA25! 🎉
Our CMO, Dr. Amy Sehnert, and co-founder, Dr. Saumya Das, presented 3 posters on SGK1 inhibition in heart failure.
Our new preprint, “A novel SGK1 inhibitor improves cardiac structure & function”, is now live: researchsquare.com/article/rs-7...
#HeartFailure #SGK1
Our CMO, Dr. Amy Sehnert, and co-founder, Dr. Saumya Das, presented 3 posters on SGK1 inhibition in heart failure.
Our new preprint, “A novel SGK1 inhibitor improves cardiac structure & function”, is now live: researchsquare.com/article/rs-7...
#HeartFailure #SGK1
Thryv Therapeutics will present 3 moderated e-posters at #AHA25 on THRV-1268, part of our SGK1 inhibitor portfolio targeting heart failure & cardiac remodeling.
📍 Nov 8–10 | New Orleans
Read more: loom.ly/gXgaJEQ
#CardioResearch #HeartFailure
📍 Nov 8–10 | New Orleans
Read more: loom.ly/gXgaJEQ
#CardioResearch #HeartFailure
November 5, 2025 at 2:59 PM
Thryv Therapeutics will present 3 moderated e-posters at #AHA25 on THRV-1268, part of our SGK1 inhibitor portfolio targeting heart failure & cardiac remodeling.
📍 Nov 8–10 | New Orleans
Read more: loom.ly/gXgaJEQ
#CardioResearch #HeartFailure
📍 Nov 8–10 | New Orleans
Read more: loom.ly/gXgaJEQ
#CardioResearch #HeartFailure
Thryv Therapeutics will join the Wells Fargo, Stifel, Jefferies & RBC investor conferences to share our vision for transforming cardiovascular care through SGK1 inhibition.
👉 Read more: loom.ly/tUk3fWY
#ThryvTherapeutics #SGK1 #Biotech #LQTS #AFib #HeartFailure
👉 Read more: loom.ly/tUk3fWY
#ThryvTherapeutics #SGK1 #Biotech #LQTS #AFib #HeartFailure
November 3, 2025 at 2:30 PM
Thryv Therapeutics will join the Wells Fargo, Stifel, Jefferies & RBC investor conferences to share our vision for transforming cardiovascular care through SGK1 inhibition.
👉 Read more: loom.ly/tUk3fWY
#ThryvTherapeutics #SGK1 #Biotech #LQTS #AFib #HeartFailure
👉 Read more: loom.ly/tUk3fWY
#ThryvTherapeutics #SGK1 #Biotech #LQTS #AFib #HeartFailure
With FDA IND clearance and investor backing, Thryv is advancing THRV-1268, our lead SGK1 inhibitor, into Phase 2/3 for Long QT Syndrome—bringing us closer to the first approved therapy for people with LQTS.
👉 loom.ly/tZj96M8
#SGK1 #LQTS #Biotech
👉 loom.ly/tZj96M8
#SGK1 #LQTS #Biotech
September 17, 2025 at 6:53 PM
With FDA IND clearance and investor backing, Thryv is advancing THRV-1268, our lead SGK1 inhibitor, into Phase 2/3 for Long QT Syndrome—bringing us closer to the first approved therapy for people with LQTS.
👉 loom.ly/tZj96M8
#SGK1 #LQTS #Biotech
👉 loom.ly/tZj96M8
#SGK1 #LQTS #Biotech
📣 We’re headed to #ESCCongress! Excited to share compelling new preclinical results on our lead SGK1 inhibitor, THRV-1268.
🗓️ Aug 30 – Heart Failure | Dr. Saumya Das
🗓️ Aug 31 – LQTS | Dr. Simona Casini
Details 👉 loom.ly/LPHc97A
#SGK1 #Cardiology
🗓️ Aug 30 – Heart Failure | Dr. Saumya Das
🗓️ Aug 31 – LQTS | Dr. Simona Casini
Details 👉 loom.ly/LPHc97A
#SGK1 #Cardiology
August 26, 2025 at 3:29 PM
📣 We’re headed to #ESCCongress! Excited to share compelling new preclinical results on our lead SGK1 inhibitor, THRV-1268.
🗓️ Aug 30 – Heart Failure | Dr. Saumya Das
🗓️ Aug 31 – LQTS | Dr. Simona Casini
Details 👉 loom.ly/LPHc97A
#SGK1 #Cardiology
🗓️ Aug 30 – Heart Failure | Dr. Saumya Das
🗓️ Aug 31 – LQTS | Dr. Simona Casini
Details 👉 loom.ly/LPHc97A
#SGK1 #Cardiology
🔬 Behind the scenes in the lab!
Our team is advancing SGK1 inhibition to help treat LQTS, AFib & heart failure. From bench to breakthrough.
#SGK1 #CardiacResearch #TeamThryv
Our team is advancing SGK1 inhibition to help treat LQTS, AFib & heart failure. From bench to breakthrough.
#SGK1 #CardiacResearch #TeamThryv
August 26, 2025 at 3:28 PM
🔬 Behind the scenes in the lab!
Our team is advancing SGK1 inhibition to help treat LQTS, AFib & heart failure. From bench to breakthrough.
#SGK1 #CardiacResearch #TeamThryv
Our team is advancing SGK1 inhibition to help treat LQTS, AFib & heart failure. From bench to breakthrough.
#SGK1 #CardiacResearch #TeamThryv
🌍 On #ClinicalTrialsDay, we celebrate the power of research—especially in rare diseases, where each trial brings hope. Thank you to the patients, researchers & HCPs driving progress.
At Thryv, we’re proud to advance treatments for LQTS, heart failure & AF. 💚
#ResearchMatters
At Thryv, we’re proud to advance treatments for LQTS, heart failure & AF. 💚
#ResearchMatters
May 20, 2025 at 5:29 PM
🌍 On #ClinicalTrialsDay, we celebrate the power of research—especially in rare diseases, where each trial brings hope. Thank you to the patients, researchers & HCPs driving progress.
At Thryv, we’re proud to advance treatments for LQTS, heart failure & AF. 💚
#ResearchMatters
At Thryv, we’re proud to advance treatments for LQTS, heart failure & AF. 💚
#ResearchMatters
Thryv to share latest clinical results of SGK1 inhibition in patients with LQTS at RBC (May 20–21) & Jefferies (June 3–5). Learn more about our SGK1 platform for LQTS, HF & AFib.
📄 Press release: loom.ly/sIJ8l0c
📩 [email protected]
#ThryvTherapeutics #SGK1 #LQTS
📄 Press release: loom.ly/sIJ8l0c
📩 [email protected]
#ThryvTherapeutics #SGK1 #LQTS
May 13, 2025 at 1:12 PM
Thryv to share latest clinical results of SGK1 inhibition in patients with LQTS at RBC (May 20–21) & Jefferies (June 3–5). Learn more about our SGK1 platform for LQTS, HF & AFib.
📄 Press release: loom.ly/sIJ8l0c
📩 [email protected]
#ThryvTherapeutics #SGK1 #LQTS
📄 Press release: loom.ly/sIJ8l0c
📩 [email protected]
#ThryvTherapeutics #SGK1 #LQTS
👩⚕️ Nurses are the heart of healthcare. On this #InternationalNursesDay, we recognize their power to shape stronger health systems.
At Thryv, we’re proud to work with nurses advancing cardiovascular care and clinical research. 💚
#ThankYouNurses #NursesTransformCare
At Thryv, we’re proud to work with nurses advancing cardiovascular care and clinical research. 💚
#ThankYouNurses #NursesTransformCare
May 12, 2025 at 1:24 PM
👩⚕️ Nurses are the heart of healthcare. On this #InternationalNursesDay, we recognize their power to shape stronger health systems.
At Thryv, we’re proud to work with nurses advancing cardiovascular care and clinical research. 💚
#ThankYouNurses #NursesTransformCare
At Thryv, we’re proud to work with nurses advancing cardiovascular care and clinical research. 💚
#ThankYouNurses #NursesTransformCare
May is #StrokeAwarenessMonth. Stroke is the most serious complication of #AFib, increasing risk 5x. At Thryv, we’re targeting SGK1 to address the biology behind AFib. Know the signs:
👤 Face drooping
💪 Arm weakness
🗣️ Speech trouble
📞 Time to call 911. #FAST #HeartHealth
👤 Face drooping
💪 Arm weakness
🗣️ Speech trouble
📞 Time to call 911. #FAST #HeartHealth
May 5, 2025 at 3:43 PM
May is #StrokeAwarenessMonth. Stroke is the most serious complication of #AFib, increasing risk 5x. At Thryv, we’re targeting SGK1 to address the biology behind AFib. Know the signs:
👤 Face drooping
💪 Arm weakness
🗣️ Speech trouble
📞 Time to call 911. #FAST #HeartHealth
👤 Face drooping
💪 Arm weakness
🗣️ Speech trouble
📞 Time to call 911. #FAST #HeartHealth
We’re proud to have a team of innovators from both sides of the border advancing treatments for Long QT Syndrome, heart failure & AFib.
With the FDA, we're united in bringing new options to those living with cardiovascular disease. 💚
#TeamThryv #LQTS #SGK1 #Biotech
With the FDA, we're united in bringing new options to those living with cardiovascular disease. 💚
#TeamThryv #LQTS #SGK1 #Biotech
April 14, 2025 at 12:29 AM
We’re proud to have a team of innovators from both sides of the border advancing treatments for Long QT Syndrome, heart failure & AFib.
With the FDA, we're united in bringing new options to those living with cardiovascular disease. 💚
#TeamThryv #LQTS #SGK1 #Biotech
With the FDA, we're united in bringing new options to those living with cardiovascular disease. 💚
#TeamThryv #LQTS #SGK1 #Biotech
Thryv Therapeutics is excited to join the 2025 Piper Sandler Virtual Cardio Day on April 1! Our leadership team will sit for a fireside chat at 11:30 a.m. ET, sharing insights on SGK1 inhibition for LQTS, HF & AFib.
📢 Read more: thryvtrx.com/news/piper-s...
#PiperSandler #SGK1 #BioTech
📢 Read more: thryvtrx.com/news/piper-s...
#PiperSandler #SGK1 #BioTech
March 27, 2025 at 6:47 PM
Thryv Therapeutics is excited to join the 2025 Piper Sandler Virtual Cardio Day on April 1! Our leadership team will sit for a fireside chat at 11:30 a.m. ET, sharing insights on SGK1 inhibition for LQTS, HF & AFib.
📢 Read more: thryvtrx.com/news/piper-s...
#PiperSandler #SGK1 #BioTech
📢 Read more: thryvtrx.com/news/piper-s...
#PiperSandler #SGK1 #BioTech
Heart failure (HF) affects millions, yet HFpEF remains difficult to treat. Many patients have obesity, hypertension, or AFib.
SGK1 may play a key role, and we’re exploring its inhibition as a potential treatment. Stay tuned for more research updates. ❤️
#HeartFailure #HFpEF #SGK1 #HeartResearch
SGK1 may play a key role, and we’re exploring its inhibition as a potential treatment. Stay tuned for more research updates. ❤️
#HeartFailure #HFpEF #SGK1 #HeartResearch
February 27, 2025 at 4:21 PM
Heart failure (HF) affects millions, yet HFpEF remains difficult to treat. Many patients have obesity, hypertension, or AFib.
SGK1 may play a key role, and we’re exploring its inhibition as a potential treatment. Stay tuned for more research updates. ❤️
#HeartFailure #HFpEF #SGK1 #HeartResearch
SGK1 may play a key role, and we’re exploring its inhibition as a potential treatment. Stay tuned for more research updates. ❤️
#HeartFailure #HFpEF #SGK1 #HeartResearch
💓 This Week, We’re Talking About AFib! #HeartMonth
AFib affects 5M+ Americans & 200K Canadians, increasing stroke & heart failure risk. Causes include high BP, heart disease, sleep apnea & aging. Symptoms range from palpitations to silent AFib.
#AFib #ThryvTherapeutics #SGK1
AFib affects 5M+ Americans & 200K Canadians, increasing stroke & heart failure risk. Causes include high BP, heart disease, sleep apnea & aging. Symptoms range from palpitations to silent AFib.
#AFib #ThryvTherapeutics #SGK1
February 25, 2025 at 2:54 PM
💓 This Week, We’re Talking About AFib! #HeartMonth
AFib affects 5M+ Americans & 200K Canadians, increasing stroke & heart failure risk. Causes include high BP, heart disease, sleep apnea & aging. Symptoms range from palpitations to silent AFib.
#AFib #ThryvTherapeutics #SGK1
AFib affects 5M+ Americans & 200K Canadians, increasing stroke & heart failure risk. Causes include high BP, heart disease, sleep apnea & aging. Symptoms range from palpitations to silent AFib.
#AFib #ThryvTherapeutics #SGK1
This week, we’re talking about heart failure 🫀 #HeartMonth
HF affects 6M+ Americans & 750K Canadians. Causes include high blood pressure, heart attacks, & diabetes. Early diagnosis & research improve outcomes.
#HeartFailure #ThryvTherapeutics
HF affects 6M+ Americans & 750K Canadians. Causes include high blood pressure, heart attacks, & diabetes. Early diagnosis & research improve outcomes.
#HeartFailure #ThryvTherapeutics
February 21, 2025 at 7:47 PM
This week, we’re talking about heart failure 🫀 #HeartMonth
HF affects 6M+ Americans & 750K Canadians. Causes include high blood pressure, heart attacks, & diabetes. Early diagnosis & research improve outcomes.
#HeartFailure #ThryvTherapeutics
HF affects 6M+ Americans & 750K Canadians. Causes include high blood pressure, heart attacks, & diabetes. Early diagnosis & research improve outcomes.
#HeartFailure #ThryvTherapeutics
❤️ CPR Saves Lives ❤️
Looking back on our 2023 CPR training! 📸 When the heart stops, every second counts—CPR can triple survival rates. For those with LQTS & other heart conditions, knowing CPR can save a life! 💡
#CPRSavesLives #HeartHealth #LQTSAwareness #HeartMonth
Looking back on our 2023 CPR training! 📸 When the heart stops, every second counts—CPR can triple survival rates. For those with LQTS & other heart conditions, knowing CPR can save a life! 💡
#CPRSavesLives #HeartHealth #LQTSAwareness #HeartMonth
February 11, 2025 at 3:50 PM
❤️ CPR Saves Lives ❤️
Looking back on our 2023 CPR training! 📸 When the heart stops, every second counts—CPR can triple survival rates. For those with LQTS & other heart conditions, knowing CPR can save a life! 💡
#CPRSavesLives #HeartHealth #LQTSAwareness #HeartMonth
Looking back on our 2023 CPR training! 📸 When the heart stops, every second counts—CPR can triple survival rates. For those with LQTS & other heart conditions, knowing CPR can save a life! 💡
#CPRSavesLives #HeartHealth #LQTSAwareness #HeartMonth
Did you know? 🫀 CVDs are the leading cause of death globally, with ~19.91M deaths in 2021 (AHA). Many are preventable with early detection & lifestyle changes! This #HeartMonth, let’s raise awareness & drive innovation in heart health. ❤️🔬 #HeartHealth #HeartMonth2025 #SGK1
February 4, 2025 at 3:10 PM
Did you know? 🫀 CVDs are the leading cause of death globally, with ~19.91M deaths in 2021 (AHA). Many are preventable with early detection & lifestyle changes! This #HeartMonth, let’s raise awareness & drive innovation in heart health. ❤️🔬 #HeartHealth #HeartMonth2025 #SGK1
Thryv Therapeutics is looking forward to participating in the 2025 Leerink Partners Global Healthcare Conference in Miami, FL Join us March 10-12 to discuss the latest advancements on our cardiovascular programs.
Schedule a meeting: [email protected]
#ThryvTherapeutics #Biotech #LeerinkPartners
Schedule a meeting: [email protected]
#ThryvTherapeutics #Biotech #LeerinkPartners
February 3, 2025 at 3:16 PM
Thryv Therapeutics is looking forward to participating in the 2025 Leerink Partners Global Healthcare Conference in Miami, FL Join us March 10-12 to discuss the latest advancements on our cardiovascular programs.
Schedule a meeting: [email protected]
#ThryvTherapeutics #Biotech #LeerinkPartners
Schedule a meeting: [email protected]
#ThryvTherapeutics #Biotech #LeerinkPartners